nodes	percent_of_prediction	percent_of_DWPC	metapath
Pyridostigmine—CYP3A4—Cytarabine—lymphatic system cancer	0.163	0.318	CbGbCtD
Pyridostigmine—CYP3A4—Teniposide—lymphatic system cancer	0.16	0.313	CbGbCtD
Pyridostigmine—CYP3A4—Mitoxantrone—lymphatic system cancer	0.112	0.219	CbGbCtD
Pyridostigmine—CYP3A4—Vincristine—lymphatic system cancer	0.0771	0.151	CbGbCtD
Pyridostigmine—Pallor—Teniposide—lymphatic system cancer	0.0154	0.0315	CcSEcCtD
Pyridostigmine—Thrombophlebitis—Mechlorethamine—lymphatic system cancer	0.0145	0.0297	CcSEcCtD
Pyridostigmine—Faecal incontinence—Carmustine—lymphatic system cancer	0.0142	0.0291	CcSEcCtD
Pyridostigmine—Abdominal cramps—Vincristine—lymphatic system cancer	0.0101	0.0208	CcSEcCtD
Pyridostigmine—Alopecia—Mechlorethamine—lymphatic system cancer	0.00767	0.0157	CcSEcCtD
Pyridostigmine—Neck pain—Carmustine—lymphatic system cancer	0.00725	0.0149	CcSEcCtD
Pyridostigmine—Urinary incontinence—Carmustine—lymphatic system cancer	0.00692	0.0142	CcSEcCtD
Pyridostigmine—Sweating increased—Fludarabine—lymphatic system cancer	0.00684	0.014	CcSEcCtD
Pyridostigmine—Vertigo—Mechlorethamine—lymphatic system cancer	0.00679	0.0139	CcSEcCtD
Pyridostigmine—Bronchitis—Fludarabine—lymphatic system cancer	0.00676	0.0138	CcSEcCtD
Pyridostigmine—Thrombophlebitis—Carmustine—lymphatic system cancer	0.00601	0.0123	CcSEcCtD
Pyridostigmine—Epistaxis—Fludarabine—lymphatic system cancer	0.00591	0.0121	CcSEcCtD
Pyridostigmine—Eye pain—Carmustine—lymphatic system cancer	0.00576	0.0118	CcSEcCtD
Pyridostigmine—Alopecia—Teniposide—lymphatic system cancer	0.00565	0.0116	CcSEcCtD
Pyridostigmine—Hypoaesthesia—Fludarabine—lymphatic system cancer	0.00559	0.0115	CcSEcCtD
Pyridostigmine—Agitation—Teniposide—lymphatic system cancer	0.00512	0.0105	CcSEcCtD
Pyridostigmine—Alopecia—Fludarabine—lymphatic system cancer	0.00497	0.0102	CcSEcCtD
Pyridostigmine—Cardiac arrest—Vincristine—lymphatic system cancer	0.00472	0.00968	CcSEcCtD
Pyridostigmine—Confusional state—Teniposide—lymphatic system cancer	0.00458	0.00939	CcSEcCtD
Pyridostigmine—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00454	0.00931	CcSEcCtD
Pyridostigmine—Agitation—Fludarabine—lymphatic system cancer	0.0045	0.00922	CcSEcCtD
Pyridostigmine—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00439	0.009	CcSEcCtD
Pyridostigmine—Hypotension—Teniposide—lymphatic system cancer	0.00425	0.0087	CcSEcCtD
Pyridostigmine—Convulsion—Fludarabine—lymphatic system cancer	0.00424	0.00869	CcSEcCtD
Pyridostigmine—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00422	0.00864	CcSEcCtD
Pyridostigmine—Myalgia—Fludarabine—lymphatic system cancer	0.00417	0.00854	CcSEcCtD
Pyridostigmine—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.0041	0.00841	CcSEcCtD
Pyridostigmine—Sweating increased—Mitoxantrone—lymphatic system cancer	0.00407	0.00834	CcSEcCtD
Pyridostigmine—Confusional state—Fludarabine—lymphatic system cancer	0.00403	0.00825	CcSEcCtD
Pyridostigmine—Vomiting—Mechlorethamine—lymphatic system cancer	0.00392	0.00803	CcSEcCtD
Pyridostigmine—Rash—Mechlorethamine—lymphatic system cancer	0.00389	0.00797	CcSEcCtD
Pyridostigmine—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00388	0.00796	CcSEcCtD
Pyridostigmine—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00386	0.00791	CcSEcCtD
Pyridostigmine—Feeling abnormal—Teniposide—lymphatic system cancer	0.00375	0.00768	CcSEcCtD
Pyridostigmine—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00373	0.00764	CcSEcCtD
Pyridostigmine—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00372	0.00762	CcSEcCtD
Pyridostigmine—Musculoskeletal stiffness—Methotrexate—lymphatic system cancer	0.0037	0.00758	CcSEcCtD
Pyridostigmine—Nausea—Mechlorethamine—lymphatic system cancer	0.00366	0.0075	CcSEcCtD
Pyridostigmine—Alopecia—Bleomycin—lymphatic system cancer	0.00364	0.00746	CcSEcCtD
Pyridostigmine—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00364	0.00746	CcSEcCtD
Pyridostigmine—Urticaria—Teniposide—lymphatic system cancer	0.00361	0.0074	CcSEcCtD
Pyridostigmine—Abdominal pain—Teniposide—lymphatic system cancer	0.00359	0.00736	CcSEcCtD
Pyridostigmine—Paraesthesia—Fludarabine—lymphatic system cancer	0.00359	0.00735	CcSEcCtD
Pyridostigmine—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00358	0.00734	CcSEcCtD
Pyridostigmine—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00342	0.007	CcSEcCtD
Pyridostigmine—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00341	0.00698	CcSEcCtD
Pyridostigmine—Hypersensitivity—Teniposide—lymphatic system cancer	0.00335	0.00686	CcSEcCtD
Pyridostigmine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00329	0.00675	CcSEcCtD
Pyridostigmine—Asthenia—Teniposide—lymphatic system cancer	0.00326	0.00668	CcSEcCtD
Pyridostigmine—Alopecia—Carmustine—lymphatic system cancer	0.00318	0.00652	CcSEcCtD
Pyridostigmine—Diarrhoea—Teniposide—lymphatic system cancer	0.00311	0.00637	CcSEcCtD
Pyridostigmine—Myalgia—Bleomycin—lymphatic system cancer	0.00306	0.00626	CcSEcCtD
Pyridostigmine—Alopecia—Vincristine—lymphatic system cancer	0.00304	0.00622	CcSEcCtD
Pyridostigmine—Alopecia—Mitoxantrone—lymphatic system cancer	0.00296	0.00606	CcSEcCtD
Pyridostigmine—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.00295	0.00605	CcSEcCtD
Pyridostigmine—Confusional state—Bleomycin—lymphatic system cancer	0.00295	0.00605	CcSEcCtD
Pyridostigmine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00294	0.00603	CcSEcCtD
Pyridostigmine—Vomiting—Teniposide—lymphatic system cancer	0.00289	0.00592	CcSEcCtD
Pyridostigmine—Agitation—Carmustine—lymphatic system cancer	0.00288	0.0059	CcSEcCtD
Pyridostigmine—Asthenia—Fludarabine—lymphatic system cancer	0.00287	0.00587	CcSEcCtD
Pyridostigmine—Rash—Teniposide—lymphatic system cancer	0.00287	0.00587	CcSEcCtD
Pyridostigmine—Dermatitis—Teniposide—lymphatic system cancer	0.00286	0.00587	CcSEcCtD
Pyridostigmine—Headache—Teniposide—lymphatic system cancer	0.00285	0.00583	CcSEcCtD
Pyridostigmine—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.00278	0.0057	CcSEcCtD
Pyridostigmine—Agitation—Vincristine—lymphatic system cancer	0.00275	0.00563	CcSEcCtD
Pyridostigmine—Hypotension—Bleomycin—lymphatic system cancer	0.00274	0.00561	CcSEcCtD
Pyridostigmine—Diarrhoea—Fludarabine—lymphatic system cancer	0.00273	0.0056	CcSEcCtD
Pyridostigmine—Convulsion—Carmustine—lymphatic system cancer	0.00271	0.00556	CcSEcCtD
Pyridostigmine—Nausea—Teniposide—lymphatic system cancer	0.0027	0.00553	CcSEcCtD
Pyridostigmine—Vertigo—Vincristine—lymphatic system cancer	0.00269	0.00551	CcSEcCtD
Pyridostigmine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00267	0.00547	CcSEcCtD
Pyridostigmine—Myalgia—Carmustine—lymphatic system cancer	0.00267	0.00546	CcSEcCtD
Pyridostigmine—Paraesthesia—Bleomycin—lymphatic system cancer	0.00263	0.00539	CcSEcCtD
Pyridostigmine—Convulsion—Vincristine—lymphatic system cancer	0.00259	0.00531	CcSEcCtD
Pyridostigmine—Confusional state—Carmustine—lymphatic system cancer	0.00258	0.00528	CcSEcCtD
Pyridostigmine—Myalgia—Vincristine—lymphatic system cancer	0.00255	0.00522	CcSEcCtD
Pyridostigmine—Vomiting—Fludarabine—lymphatic system cancer	0.00254	0.0052	CcSEcCtD
Pyridostigmine—Convulsion—Mitoxantrone—lymphatic system cancer	0.00252	0.00517	CcSEcCtD
Pyridostigmine—Rash—Fludarabine—lymphatic system cancer	0.00252	0.00516	CcSEcCtD
Pyridostigmine—Dermatitis—Fludarabine—lymphatic system cancer	0.00252	0.00516	CcSEcCtD
Pyridostigmine—Headache—Fludarabine—lymphatic system cancer	0.0025	0.00513	CcSEcCtD
Pyridostigmine—Myalgia—Mitoxantrone—lymphatic system cancer	0.00248	0.00508	CcSEcCtD
Pyridostigmine—Lethargy—Methotrexate—lymphatic system cancer	0.00246	0.00504	CcSEcCtD
Pyridostigmine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00241	0.00495	CcSEcCtD
Pyridostigmine—Confusional state—Mitoxantrone—lymphatic system cancer	0.0024	0.00491	CcSEcCtD
Pyridostigmine—Hypotension—Carmustine—lymphatic system cancer	0.00239	0.0049	CcSEcCtD
Pyridostigmine—Nausea—Fludarabine—lymphatic system cancer	0.00237	0.00486	CcSEcCtD
Pyridostigmine—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00236	0.00483	CcSEcCtD
Pyridostigmine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00233	0.00477	CcSEcCtD
Pyridostigmine—Urticaria—Bleomycin—lymphatic system cancer	0.00233	0.00477	CcSEcCtD
Pyridostigmine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.0023	0.00471	CcSEcCtD
Pyridostigmine—Paraesthesia—Carmustine—lymphatic system cancer	0.0023	0.0047	CcSEcCtD
Pyridostigmine—Hypotension—Vincristine—lymphatic system cancer	0.00228	0.00467	CcSEcCtD
Pyridostigmine—Somnolence—Carmustine—lymphatic system cancer	0.00227	0.00466	CcSEcCtD
Pyridostigmine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00222	0.00456	CcSEcCtD
Pyridostigmine—Hypotension—Mitoxantrone—lymphatic system cancer	0.00222	0.00455	CcSEcCtD
Pyridostigmine—Paraesthesia—Vincristine—lymphatic system cancer	0.00219	0.00449	CcSEcCtD
Pyridostigmine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00217	0.00444	CcSEcCtD
Pyridostigmine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00216	0.00442	CcSEcCtD
Pyridostigmine—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00213	0.00437	CcSEcCtD
Pyridostigmine—Somnolence—Mitoxantrone—lymphatic system cancer	0.00211	0.00433	CcSEcCtD
Pyridostigmine—Feeling abnormal—Carmustine—lymphatic system cancer	0.00211	0.00432	CcSEcCtD
Pyridostigmine—Asthenia—Bleomycin—lymphatic system cancer	0.0021	0.00431	CcSEcCtD
Pyridostigmine—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00209	0.00428	CcSEcCtD
Pyridostigmine—Asthma—Methotrexate—lymphatic system cancer	0.00208	0.00427	CcSEcCtD
Pyridostigmine—Abdominal pain—Carmustine—lymphatic system cancer	0.00202	0.00414	CcSEcCtD
Pyridostigmine—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.002	0.00409	CcSEcCtD
Pyridostigmine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00196	0.00401	CcSEcCtD
Pyridostigmine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00194	0.00398	CcSEcCtD
Pyridostigmine—Abdominal pain—Vincristine—lymphatic system cancer	0.00193	0.00395	CcSEcCtD
Pyridostigmine—Urticaria—Mitoxantrone—lymphatic system cancer	0.00189	0.00387	CcSEcCtD
Pyridostigmine—Hypersensitivity—Carmustine—lymphatic system cancer	0.00188	0.00386	CcSEcCtD
Pyridostigmine—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00188	0.00385	CcSEcCtD
Pyridostigmine—Vomiting—Bleomycin—lymphatic system cancer	0.00186	0.00382	CcSEcCtD
Pyridostigmine—Drowsiness—Methotrexate—lymphatic system cancer	0.00186	0.0038	CcSEcCtD
Pyridostigmine—Rash—Bleomycin—lymphatic system cancer	0.00185	0.00378	CcSEcCtD
Pyridostigmine—Dermatitis—Bleomycin—lymphatic system cancer	0.00184	0.00378	CcSEcCtD
Pyridostigmine—Asthenia—Carmustine—lymphatic system cancer	0.00183	0.00376	CcSEcCtD
Pyridostigmine—Hypersensitivity—Vincristine—lymphatic system cancer	0.0018	0.00368	CcSEcCtD
Pyridostigmine—Epistaxis—Methotrexate—lymphatic system cancer	0.00175	0.00359	CcSEcCtD
Pyridostigmine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00175	0.00359	CcSEcCtD
Pyridostigmine—Asthenia—Vincristine—lymphatic system cancer	0.00175	0.00359	CcSEcCtD
Pyridostigmine—Diarrhoea—Carmustine—lymphatic system cancer	0.00175	0.00358	CcSEcCtD
Pyridostigmine—Nausea—Bleomycin—lymphatic system cancer	0.00174	0.00356	CcSEcCtD
Pyridostigmine—Asthenia—Mitoxantrone—lymphatic system cancer	0.00171	0.00349	CcSEcCtD
Pyridostigmine—Diarrhoea—Vincristine—lymphatic system cancer	0.00167	0.00342	CcSEcCtD
Pyridostigmine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00163	0.00333	CcSEcCtD
Pyridostigmine—Vomiting—Carmustine—lymphatic system cancer	0.00163	0.00333	CcSEcCtD
Pyridostigmine—Rash—Carmustine—lymphatic system cancer	0.00161	0.0033	CcSEcCtD
Pyridostigmine—Dermatitis—Carmustine—lymphatic system cancer	0.00161	0.0033	CcSEcCtD
Pyridostigmine—Headache—Carmustine—lymphatic system cancer	0.0016	0.00328	CcSEcCtD
Pyridostigmine—Vomiting—Vincristine—lymphatic system cancer	0.00155	0.00318	CcSEcCtD
Pyridostigmine—Rash—Vincristine—lymphatic system cancer	0.00154	0.00315	CcSEcCtD
Pyridostigmine—Dermatitis—Vincristine—lymphatic system cancer	0.00154	0.00315	CcSEcCtD
Pyridostigmine—Headache—Vincristine—lymphatic system cancer	0.00153	0.00313	CcSEcCtD
Pyridostigmine—Nausea—Carmustine—lymphatic system cancer	0.00152	0.00311	CcSEcCtD
Pyridostigmine—Vomiting—Mitoxantrone—lymphatic system cancer	0.00151	0.0031	CcSEcCtD
Pyridostigmine—Rash—Mitoxantrone—lymphatic system cancer	0.0015	0.00307	CcSEcCtD
Pyridostigmine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.0015	0.00307	CcSEcCtD
Pyridostigmine—Headache—Mitoxantrone—lymphatic system cancer	0.00149	0.00305	CcSEcCtD
Pyridostigmine—Alopecia—Methotrexate—lymphatic system cancer	0.00147	0.00302	CcSEcCtD
Pyridostigmine—Nausea—Vincristine—lymphatic system cancer	0.00145	0.00297	CcSEcCtD
Pyridostigmine—Nausea—Mitoxantrone—lymphatic system cancer	0.00141	0.00289	CcSEcCtD
Pyridostigmine—Vertigo—Methotrexate—lymphatic system cancer	0.0013	0.00267	CcSEcCtD
Pyridostigmine—Convulsion—Methotrexate—lymphatic system cancer	0.00126	0.00258	CcSEcCtD
Pyridostigmine—Myalgia—Methotrexate—lymphatic system cancer	0.00124	0.00253	CcSEcCtD
Pyridostigmine—Confusional state—Methotrexate—lymphatic system cancer	0.00119	0.00245	CcSEcCtD
Pyridostigmine—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00114	0.00235	CcSEcCtD
Pyridostigmine—Hypotension—Methotrexate—lymphatic system cancer	0.00111	0.00227	CcSEcCtD
Pyridostigmine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00108	0.00221	CcSEcCtD
Pyridostigmine—Paraesthesia—Methotrexate—lymphatic system cancer	0.00106	0.00218	CcSEcCtD
Pyridostigmine—Somnolence—Methotrexate—lymphatic system cancer	0.00105	0.00216	CcSEcCtD
Pyridostigmine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000976	0.002	CcSEcCtD
Pyridostigmine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000968	0.00198	CcSEcCtD
Pyridostigmine—Urticaria—Methotrexate—lymphatic system cancer	0.000941	0.00193	CcSEcCtD
Pyridostigmine—Abdominal pain—Methotrexate—lymphatic system cancer	0.000936	0.00192	CcSEcCtD
Pyridostigmine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000872	0.00179	CcSEcCtD
Pyridostigmine—Asthenia—Methotrexate—lymphatic system cancer	0.00085	0.00174	CcSEcCtD
Pyridostigmine—Diarrhoea—Methotrexate—lymphatic system cancer	0.00081	0.00166	CcSEcCtD
Pyridostigmine—Vomiting—Methotrexate—lymphatic system cancer	0.000753	0.00154	CcSEcCtD
Pyridostigmine—Rash—Methotrexate—lymphatic system cancer	0.000747	0.00153	CcSEcCtD
Pyridostigmine—Dermatitis—Methotrexate—lymphatic system cancer	0.000746	0.00153	CcSEcCtD
Pyridostigmine—Headache—Methotrexate—lymphatic system cancer	0.000742	0.00152	CcSEcCtD
Pyridostigmine—Nausea—Methotrexate—lymphatic system cancer	0.000703	0.00144	CcSEcCtD
